An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-III)
Phase of Trial: Phase III
Latest Information Update: 26 Feb 2016
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms TURQUOISE-III
- Sponsors AbbVie
- 26 Feb 2016 According to an AbbVie media release, the European Committee for Medicinal Products for Human Use (CHMP) of the EMA has granted a positive opinion for the use of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) without ribavirin in chronic hepatitis C virus (HCV) infected genotype 1b (GT1b) patients with compensated cirrhosis (Child-Pugh A).
- 07 Jan 2016 Results published in Enanta Pharmaceuticals media release.
- 07 Jan 2016 Results published in AbbVie media release.